Celcuity (CELC): Landmark Approval Collides With A Costly Launch
On August 13, Celcuity (NASDAQ:CELC) walked investors through a quarter unlike any in the company's history.
Celcuity Inc. (CELC)
Market is closed
Sector: Services-Medical Laboratories
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Baker Bros. Advisors Julian Baker And Felix Baker | 7,915,792 | $828,150,159 | 4.15% | |
| 2. | VenBio Select Advisor Kurt Von Emster | 3,400,000 | $355,708,000 | +1% | 3.19% |
| 3. | Perceptive Advisors Joseph Edelman | 3,197,200 | $334,491,064 | +3% | 5.02% |
| 4. | Soleus Capital Guy Levy | 1,704,318 | $178,305,749 | +33% | 6.14% |
| 5. | Deerfield Management James E. Flynn | 1,451,014 | $151,805,085 | -16% | 1.58% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $58.02 | 4,212 | $244,395.40 | 7,211,484 | 2025-09-08 | Filing | |
| $58.02 | 388 | $22,513.16 | 704,308 | 2025-09-08 | Filing | |
| $56.22 | 151,524 | $8,518,679.28 | 7,207,272 | 2025-09-08 | Filing | |
| $56.22 | 13,976 | $785,730.72 | 703,920 | 2025-09-08 | Filing | |
| $10.32 | 10,000 | $103,187.00 | 10,250 | 2023-05-22 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $102.50 | 2,838,632 | $290,959,780.00 | 4,372,852 | 2026-07-14 | Filing | |
| $102.50 | 261,368 | $26,790,220.00 | 442,940 | 2026-07-14 | Filing | |
| $140.68 | 25,000 | $3,517,000.00 | 65,000 | 2026-05-04 | Filing | |
| $143.24 | 365 | $52,281.80 | 6,760 | 2026-05-04 | Filing | |
| $142.04 | 2,825 | $401,251.14 | 7,125 | 2026-05-04 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 3,304,903 | $345,758,952 | 2.95% | |
| 2. | 3,018,785 | $315,825,285 | 0% | |
| 3. | 112,901,000 | $254,455,960 | 1.32% | |
| 4. | 1,955,304 | $204,556,764 | 0.01% | |
| 5. | 1,874,137 | $196,072,213 | 0% |
News See All
12 Best High Short Interest Stocks With Highest Upside Potential
On May 29, Melissa Brown, Managing Director of Investment Decision Research, joined BNN Bloomberg to assess the health of the US economy.
Celcuity Inc. (NASDAQ:CELC) Q1 2026 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen, and welcome to the Celcuity First Quarter 2026 Financial Results Call Webcast.
Billionaire Joe Edelman's 10 Stock Picks with Huge Upside Potential
Joseph Edelman, the billionaire chief of New York-based Perceptive Advisors, specializes in the biotechnology and life sciences sectors.
Celcuity Inc. (NASDAQ:CELC) Q4 2025 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen, and welcome to the Celcuity Fourth Quarter and Full Year 2025 Financial Call.
Celcuity (CELC) Draws Investor Attention as Precision Oncology Strategy Advances
Apis Capital Advisors’ Apis Flagship Fund released its Q4 2025 investor letter. A copy of the letter can be downloaded here.
Wells Fargo Initiates Coverage On Celcuity Inc. (CELC)
On December 12, 2025, TheFly reported that Wells Fargo started covering Celcuity Inc. (NASDAQ:CELC) with a $126 price target and an Overweight rating.
Celcuity (CELC) Surges 662% in 2025 on Breast Cancer Treatment Trial Results
In an updated report which was presented to the 2025 San Antonio Breast Cancer Symposium early last month, Celcuity Inc.
Celcuity (CELC)'s Clinical Success and M&A Potential Underpin Wolfe Research’s Bullish View
Celcuity Inc. (NASDAQ:CELC) is among the hottest SMID-cap stocks so far in 2025.